Patients’ health care resources utilization and costs estimation across cardiovascular risk categories: insights from the LATINO study

Cristina Gavina, Alexandra Borges, Marta Afonso-Silva, Inês Fortuna, Mariana Canelas-Pais, Rita Amaral, Inês Costa, Daniel Seabra, Francisco Araújo and Tiago Taveira-Gomes ()
Additional contact information
Cristina Gavina: Hospital Pedro Hispano-Unidad Local de Saúde Matosinhos
Alexandra Borges: Unidade Local de Saúde Matosinhos
Marta Afonso-Silva: Novartis Farma, Produtos Farmacêuticos SA
Inês Fortuna: MTG Research and Development Lab
Mariana Canelas-Pais: MTG Research and Development Lab
Rita Amaral: MTG Research and Development Lab
Inês Costa: Novartis Farma, Produtos Farmacêuticos S.A
Daniel Seabra: Hospital Pedro Hispano - Unidade Local de Saúde de Matosinhos
Francisco Araújo: Hospital Lusíadas
Tiago Taveira-Gomes: University of Porto

Health Economics Review, 2024, vol. 14, issue 1, 1-11

Abstract: Abstract Background Atherosclerotic Cardiovascular Disease (ASCVD) is a global public health concern. This study aimed to estimate the healthcare resource utilization (HRU) and costs stratified by cardiovascular disease (CVD) risk categories using real-world evidence, in a regional population in Portugal. Methods This is a retrospective observational study, using data from Electronic Health Records between 2017 and 2021. Patients aged ≥ 40 years, and with at least one general practitioner (GP) appointment in the 3 years before 31st of December 2019, were included. CVD risk categories were determined based on 2021 ESC prevention guidelines. HRU encompassed hospital data (hospitalizations, outpatient and emergency room visits) and GP appointments. Total direct costs per patient were calculated based on the reference cost of the Portuguese legislation for payment methodology on Diagnosis-Related Groups (DRGs). Results Analysis of 3 122 695 episodes, revealed consistent HRU and costs across the five years. Very high-risk patients, showed higher HRU, particularly in hospital admissions. Costs tended to rise with higher CVD risk level. Very high-risk patients with ASCVD had higher costs for hospital admissions, while low-to-moderate risk patients had higher costs for GP visits. Despite a smaller proportion, very high-risk patients with prior ASCVD represent the highest costs per patient across healthcare settings (from 115€ in emergency visits to 2 673€ in hospitalizations), followed by very high-risk patients without prior ASCVD (ASCVD-risk equivalents). Conclusion This study revealed a substantial HRU and costs by patients with very high CVD risk, particularly those with prior ASCVD. Moreover, ASCVD-risk equivalents emerge as notable consumers, emphasizing the importance of risk assessment and preventive measures in cost-effective management of these patients.

Keywords: Atherosclerosis; Cardiovascular diseases; Risk factors; Electronic health records; Health resources; Health care costs (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-024-00550-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00550-2

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-024-00550-2

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().